Find Cancer Clinical Trials Across Leading Hospitals and Research Centers

Trial ID: SYS6010-021

SYS6010-021 (NCT07406542) is a Phase III randomized study in China comparing SYS6010, an investigational EGFR-targeted antibody-drug conjugate, against standard chemotherapy in adults with HER2-negative, EGFR-positive recurrent or metastatic breast cancer who have received prior chemotherapy. The trial plans to enroll approximately 400 patients across multiple centers. CancerFax helps patients and families understand whether this trial may be relevant and coordinate pre-screening review with the trial centers.

This Phase I/II trial tests whether autologous tumor-infiltrating lymphocytes (TIL) — immune cells harvested from a patient's own tumor — combined with pembrolizumab (Keytruda) can produce measurable responses in patients with advanced or metastatic lung cancer who have exhausted standard therapies. The trial is actively recruiting at District One Hospital, Beijing. CancerFax helps eligible international patients navigate the access process.

This prospective randomized trial tests whether cytokine-induced killer (CIK) cells — and an advanced mRNA-engineered variant — can rescue disease control in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) whose CAR-T cells have lost functional activity within 6 months of infusion. The trial is actively recruiting at Beijing GoBroad Hospital, one of China's most experienced CAR-T and cell therapy centres. CancerFax supports international families navigating access.

Trial ID: BAH248

This Phase I/II study at District One Hospital, Beijing evaluates autologous tumor-infiltrating lymphocytes (TIL) combined with Pembrolizumab (Keytruda) and Aldesleukin (IL-2) for patients with advanced or metastatic colorectal cancer who have failed standard treatments. CancerFax can help organize your records and coordinate eligibility review with the trial team.

This multi-center Chinese study compares two strategies for patients with refractory or relapsed B-cell acute lymphoblastic leukemia: sequential CD19 and CD22 CAR-T cell infusion versus CD19 CAR-T followed by stem cell transplant. CancerFax helps patients and families organize medical records, coordinate remote review, and explore whether this pathway may be appropriate.

NCT07520357 is a Phase II single-arm trial evaluating SHR-A1904 — Hengrui's CLDN18.2-targeting antibody-drug conjugate (ADC) — as second-line or later monotherapy in patients with advanced neuroendocrine carcinoma (NEC) who have progressed after platinum-based chemotherapy. The trial is sponsored by Beijing GoBroad Hospital and led by Professor Ming Lu — Chief Physician of the Department of Gastrointestinal Oncology at Peking University Cancer Hospital and Beijing GoBroad Hospital, and China's leading clinician-researcher in neuroendocrine neoplasm treatment. The trial is expected to open for enrollment in April 2026. CancerFax helps eligible patients prepare records and connect with the trial team in advance of opening.

Trial ID: JR-01

NCT01691625 was a prospective interventional study conducted at Capital Medical University Cancer Center, Beijing, evaluating whether autologous dendritic cell and cytokine-induced killer (DC-CIK) cell immunotherapy, added to standard concurrent chemoradiation, could improve quality of life and progression-free survival in patients with locally advanced esophageal carcinoma. The study was led by Dr. Jun Ren MD PhD — Director of Capital Medical University Cancer Center and a internationally recognised pioneer in DC-CIK immunotherapy. This trial is now closed. This page provides scientific context and connects patients to related current options.

Trial ID: BAH249

This Phase I/II study at District One Hospital, Beijing evaluates autologous tumor-infiltrating lymphocytes (TIL) therapy combined with Pembrolizumab (Keytruda) and Aldesleukin (IL-2) for patients with advanced or metastatic breast cancer — including triple-negative breast cancer — who have exhausted standard treatment options. CancerFax helps international patients organize records and access the trial team.

A Phase 1/2 single-arm study at Beijing GoBroad Hospital testing CD19-BCMA dual-target CAR-T cell therapy in patients with refractory lupus nephritis, systemic sclerosis, or primary Sjögren syndrome with pulmonary artery hypertension. CancerFax helps international patients organize records, coordinate translation, and request preliminary review by the trial team.

Trial ID: BJGBYY-IIT-LCYJ-2025-025

An investigator-initiated study at Beijing GoBroad Hospital evaluating an off-the-shelf, umbilical cord blood derived dual CD19-BCMA CAR-T cell therapy for patients with refractory lupus nephritis, systemic sclerosis, or primary Sjogren's syndrome with pulmonary arterial hypertension. CancerFax helps families review records, coordinate communication with the trial team, and understand whether this advanced cell therapy pathway may be relevant.

NCT06618313 is a first-in-human dose-escalation study evaluating JCXH-213 — Immorna's mRNA-LNP based in vivo CAR therapy targeting CD19 — in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Unlike conventional CAR-T therapy, JCXH-213 requires no leukapheresis, no ex vivo cell manufacturing, and no lymphodepletion chemotherapy. It is administered as a standard intravenous infusion that reprograms the patient's own T cells, NK cells, and macrophages directly inside the body. The trial is recruiting at Beijing GoBroad Hospital under the leadership of Dr. Kai Hu. This represents a genuinely new era of programmable immunotherapy. CancerFax helps eligible international patients navigate access.

Trial ID: JR-02

NCT01691664 (internal ID: JR-02) was a prospective interventional study at Capital Medical University Cancer Center, Beijing Shijitan Hospital, evaluating whether autologous DC-CIK cell immunotherapy added to post-operative adjuvant radiation could improve disease-free survival in patients who had undergone curative-intent surgical resection of esophageal cancer. The study was led by Dr. Jun Ren MD PhD — Director of CMUCC, Beijing Key Laboratory for Therapeutic Cancer Vaccines, and a leading figure in DC-CIK immunotherapy research. The registry has not been updated since October 2019 and the study's estimated completion dates have both passed. This trial is not recruiting. This page is a scientific reference for patients and clinicians interested in this treatment approach.

Trial ID: A306-IIT-BJGB01

An investigator-initiated study at Beijing GoBroad Hospital that evaluated an engineered anti-ALPP CAR-T cell therapy in adults with ALPP-positive recurrent or metastatic solid tumors. The sponsor has since terminated the trial as a strategic portfolio decision. CancerFax shares this information transparently and helps families explore other relevant ALPP-targeted, CAR-T and advanced cell therapy options.

A Phase 1/2 multi-center study evaluating CD5-targeted CAR T-cell therapy in adults and children with relapsed or refractory CD5-positive T-cell leukemia or lymphoma. CancerFax helps patients and families understand the trial, organize medical records, and coordinate with the trial team in China.

Trial ID: BJGBYY-IIT-LCYJ-2025-031

NCT07003555 is a Phase 1, multicenter, open-label trial evaluating dual-targeting BCMA and CD19 CAR-T cell therapy specifically in patients with relapsed or refractory multiple myeloma (RRMM) who have measurable extramedullary lesions — a high-risk subgroup that responds poorly to single-target BCMA CAR-T alone and represents one of the most urgent unmet needs in multiple myeloma. The trial is sponsored by Beijing GoBroad Hospital with collaborators at Shanghai Liquan Hospital and Ruijin Hospital (Shanghai). CancerFax helps eligible international patients navigate access to this trial.

Trial ID: RF8-MM

NCT03393858 (internal ID: RF8-MM) was a Phase I/II prospective study at Capital Medical University Cancer Center, Beijing Shijitan Hospital, investigating whether a novel triple-combination regimen — autologous DC-CIK adoptive cell therapy, anti-PD-1 checkpoint blockade, and radiofrequency hyperthermia via the Thermotron RF-8EX device — could improve progression-free survival and quality of life in patients with advanced malignant mesothelioma who had failed or refused platinum-based chemotherapy. The trial was terminated due to insufficient patient enrollment — only 10 patients were enrolled. This page documents the scientific rationale and contextualises the treatment approach against the current mesothelioma landscape.

Trial ID: V001-CAMS-001

A first-in-human Phase 1 platform study at the Cancer Hospital, Chinese Academy of Medical Sciences in Beijing, evaluating an in vivo CAR-T therapy (V001 Injection) across BCMA, GPRC5D, DLL3 and FcRH5 cohorts for adults with relapsed or refractory advanced malignancies. CancerFax can help international patients understand whether this trial may be relevant and coordinate with the CAMS team.

Trial ID: CT041-CG4006

NCT03874897 (CT041-CG4006) was a landmark multi-center Phase 1 study evaluating CT041 — an autologous anti-CLDN18.2 CAR-T therapy — in patients with CLDN18.2-positive advanced solid tumors who had exhausted prior systemic treatment. Results published in Nature Medicine established CLDN18.2 CAR-T as a clinically viable approach. CancerFax can help you understand the published findings and navigate currently available access pathways.

Trial ID: BAH2472

This Phase I/II trial investigates whether autologous tumor-infiltrating lymphocytes (TIL) — immune cells extracted from the patient's own brain tumor — combined with pembrolizumab (Keytruda) can produce measurable responses in patients with advanced gliomas, glioblastoma, and meningiomas who have failed standard therapies. The trial is actively recruiting at District One Hospital in Beijing. CancerFax helps eligible international patients navigate the access and preparation process.

NCT05032599 was a first-in-human Phase 1 trial of allogeneic, CD5-gene-edited CAR-T cells derived from haematopoietic stem cell transplant donors, tested in patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) — most of whom had previously failed CD7-directed CAR-T therapy. All 16 patients who received infusions achieved complete remission by day 30 (100% ORR). The trial registry was terminated due to institutional restructuring at Beijing Boren Hospital, not due to safety or efficacy concerns. Full results were published in Nature Medicine (January 2025). This page documents the published findings and connects patients to currently available options.

Trial ID: JWCAR029-MCL-001

A Phase 2 study evaluating Relma-cel, a CD19-directed CAR-T cell therapy, in adults with relapsed or refractory mantle cell lymphoma in China. CancerFax helps patients and families review eligibility, organise records, and coordinate with leading trial centres.